Lamotrigine Shortage: What Providers and Prescribers Need to Know in 2026

Lamotrigine is the most commonly prescribed mood stabilizer in the United States, with over 10 million prescriptions written in 2023, and a cornerstone anticonvulsant for epilepsy and Lennox-Gastaut syndrome. While it does not appear on the FDA's official drug shortage list in 2026, neurologists, epileptologists, psychiatrists, and primary care physicians are increasingly encountering patients who cannot fill their lamotrigine prescriptions — particularly for specific formulations or at specific pharmacy chains.

This clinical briefing covers the current supply picture, what's driving pharmacy-level stock-outs, prescribing strategies to protect your patients, and resources to share with your clinical team.

Current Availability Status (2026)

Lamotrigine immediate-release (IR) tablets in standard strengths (25 mg, 100 mg, 150 mg, 200 mg) remain broadly available across the US generic market. Multiple manufacturers (including Teva, Mylan, Aurobindo, Sun Pharma, and others) hold ANDA approvals, providing supply redundancy.

The more clinically relevant availability issues are with:

Lamotrigine ODT (orally disintegrating tablets): Fewer generic manufacturers; lower prescription volume means many pharmacies special-order rather than stock routinely. Patients with swallowing difficulties or young children needing ODT formulations are at higher risk of supply interruptions.

Lamotrigine XR (extended-release): Once-daily adherence benefit for appropriate patients, but less widely stocked than IR. If XR is unavailable, IR at equivalent total daily dose is a reasonable bridge — though the manufacturer switch requires clinical documentation and patient counseling.

Lamotrigine oral suspension (Subvenite, 10 mg/mL): Approved September 2025. Distribution is in ramp-up phase and many pharmacies do not yet carry it. For pediatric patients or those unable to swallow tablets, advance planning and specialty pharmacy referral may be required.

Low-dose starter pack formulations (2 mg, 5 mg chewable tablets): Used during initiation titration. These pediatric-oriented strengths are not universally stocked and may require advance ordering when initiating therapy.

Supply Chain Factors Driving Pharmacy-Level Stock-Outs

Understanding why stock-outs occur helps prescribers anticipate patient risk and counsel proactively:

Thin generic margins create manufacturer fragility. Generic lamotrigine can cost as little as $4-$10 per month with discount programs. Extremely thin margins mean manufacturers invest minimally in excess capacity — any production disruption has an outsized impact.

International supply chain interdependence. The API (active pharmaceutical ingredient) for lamotrigine is manufactured globally. Canada experienced significant supply disruptions in 2024-2025; Australia listed multiple lamotrigine formulations on its TGA shortage database extending into 2026. US producers share global API sourcing, meaning international disruptions can affect domestic supply timelines.

Wholesaler distribution heterogeneity. Chain pharmacies, independent pharmacies, and grocery store pharmacies may use different wholesalers with different manufacturer contracts. A patient's usual CVS or Walgreens may be out of stock while an independent 3 miles away has ample supply from a different wholesaler.

Manufacturer lot recalls. In January 2020, Taro Pharmaceuticals conducted a voluntary nationwide recall for a specific lot of lamotrigine tablets due to cross-contamination. Manufacturer-specific recalls reduce available supply instantly.

Patient Safety Considerations When Lamotrigine Is Unavailable

The clinical stakes of lamotrigine discontinuation are high, particularly for epilepsy patients:

Status epilepticus risk: Abrupt discontinuation of any AED — including lamotrigine — carries a risk of status epilepticus. This is especially true for patients on lamotrigine monotherapy who have achieved long-term seizure control.

SUDEP risk: Sudden Unexpected Death in Epilepsy is associated with poorly controlled seizures. Supply disruptions that cause even brief windows of reduced medication coverage increase SUDEP risk.

Driving and occupational consequences: A breakthrough seizure may reset the seizure-free period required for driving in most states (typically 3-12 months). For patients whose livelihood or independence depends on driving, a medication supply disruption has cascading social and economic consequences.

Bipolar destabilization: For bipolar I patients on lamotrigine maintenance, supply disruptions increase risk of depressive episode recurrence, which may lead to hospitalization, self-harm risk, or significant functional impairment.

Prescribing Strategies to Protect Vulnerable Patients

Proactive strategies that reduce patient risk during supply disruptions:

Prescribe 90-day supplies where permitted. Reducing refill frequency reduces the number of opportunities for a supply disruption to catch a patient unprepared. Most payers cover 90-day fills for maintenance medications.

Educate all lamotrigine patients proactively. Counsel patients to refill 7-10 days before their supply runs out. Remind them that lamotrigine cannot be stopped abruptly and they should call immediately if they encounter a supply problem.

Specify formulation clearly on prescriptions. Clearly write "lamotrigine immediate-release tablets" vs. "lamotrigine XR" vs. "lamotrigine ODT" to prevent inadvertent substitution by the pharmacist.

For non-urgent formulation switches (XR to IR), document clinically. Conversion from XR to IR at equivalent total daily dose is pharmacologically reasonable and widely accepted. Document the reason and confirm equivalent total daily dosing in your note.

Caution around manufacturer switches for seizure patients. While all generic lamotrigine products are AB-rated, the American Epilepsy Society and Epilepsy Foundation have historically advised caution when switching AED manufacturers in well-controlled patients. If your patient reports a change in seizure threshold or new symptoms after a manufacturer switch, document their preferred NDC.

Leverage pharmacy locator tools. When a patient reports they cannot fill their lamotrigine, your office staff can use medfinder for providers to help identify which nearby pharmacies have the medication in stock — rather than placing the search burden entirely on a distressed patient.

When Therapeutic Substitution Is Necessary

If lamotrigine truly cannot be sourced and a therapeutic alternative is required, the transition must be managed carefully:

For focal seizures: Levetiracetam (Keppra) or oxcarbazepine (Trileptal) are commonly used alternatives. Levetiracetam has minimal drug interactions but carries psychiatric side effect risk.

For generalized seizures: Valproate or levetiracetam are typically first-line alternatives. Valproate has teratogenicity concerns in women of childbearing potential.

For bipolar maintenance: Lithium has comparable efficacy data for bipolar maintenance and is the most evidence-based alternative. Quetiapine is also FDA-approved for bipolar depression. Any switch should be carefully cross-tapered to avoid destabilization.

Resources for Your Clinical Team

medfinder for Providers — real-time pharmacy availability lookup to help patients find lamotrigine in stock

FDA Drug Shortage Database: accessdata.fda.gov — official source for declared national shortages

ASHP Drug Shortages Resource Center: ashp.org/drug-shortages — clinical management guidance

American Epilepsy Society (aesnet.org) — clinical alerts and AED shortage guidance

For a patient-facing version of this guidance, see: How to Help Your Patients Find Lamotrigine in Stock: A Provider's Guide.